Amended Current Report Filing (8-k/a)
August 21 2018 - 9:13AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported): August 21, 2018
OWC
PHARMACEUTICAL RESEARCH CORP.
(Exact Name of Registrant as Specified in its Charter)
Commission
File No.: 0-54856
Delaware
|
|
98-0573566
|
(State
of
Incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
2
Ben Gurion Street, Ramat Gan, Israel
|
|
5257334
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
Telephone Number, including area code: +972-72-260-8004
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
As
part of the Registrant’s preparation for its Phase II efficacy study (the “Psoriasis Study”) of its cannabinoid-based
ointment for the treatment of skin diseases, the Registrant appointed Professor Yuval Ramot as a consultant. Professor
Ramot is the Head of the Psoriasis Clinic at Hadassah – Hebrew University Medical Center in Jerusalem, Israel (“Hadassah”)
and specializes in Dermatology and Venereology. Professor Ramot holds an MD and an MSc degree in Biochemistry from
the Hebrew University of Jerusalem, Israel. Following his medical training, he specialized in hair research in the Department
of Dermatology at Lübeck University, Germany. In March 2016, he joined the Department of Dermatology at Hadassah and the
Center for Genetic Diseases of the Skin and Hair, where he focuses on research of genetic skin and hair diseases and toxicology
of the skin. His main clinical interest is in inflammatory diseases of the skin. He is the director of the psoriasis and hidradenitis
suppurativa clinics at Hadassah. He is the recipient of the Minerva Post-doctoral Fellowship and the Young Dermatologist International
Achievement Award. He has also co-authored 10 chapters in books and more than 135 articles in peer-reviewed journals.
On
August 20, 2018, Ms. Hannah Feuer, a member of the Registrant’s board of directors and Chairperson of the Registrant’s
audit committee, resigned as director and Chairperson of the audit committee, effective immediately. Ms. Feuer stated she was
resigning all board of directors and committee memberships on which she currently serves as a condition of acceptance related
to her expected appointment to a banking corporation. Ms. Feuer’s resignation is not the result of any disagreement with
the policies, practices or procedures of the Registrant. Ms. Feuer’s letter of resignation is attached hereto as Exhibit
17.1.
Item
9.01
|
Financial
Statements and Exhibits
|
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
OWC Pharmaceutical Research Corp.
|
|
|
|
|
By:
|
/s/
Mordechai Bignitz
|
|
Name:
|
Mordechai
Bignitz
|
|
Title:
|
Chief
Executive Officer
|
Date:
August 21, 2018
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Aug 2024 to Sep 2024
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Sep 2023 to Sep 2024